Content about UN Court

November 22, 2013

Canadian pharmacy retailer Shoppers Drug Mart has announced that the Supreme Court of Canada has upheld the Dec. 23, 2011, decision of the Court of Appeal of Ontario that restored the prohibition on private-label generic drug products in the Province of Ontario, which was subsequent to a decision of the Ontario Divisional Court dated Feb. 3, 2011, that declared the regulatory restrictions in respect of private-label generic drug products to be invalid.

TORONTO — Canadian pharmacy retailer Shoppers Drug Mart has announced that the Supreme Court of Canada has upheld the Dec. 23, 2011, decision of the Court of Appeal of Ontario that restored the prohibition on private-label generic drug products in the Province of Ontario, which was subsequent to a decision of the Ontario Divisional Court dated Feb. 3, 2011, that declared the regulatory restrictions in respect of private-label generic drug products to be invalid.

August 8, 2013

The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.

The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.

June 24, 2013

Generic drug makers cannot be held liable if patients suffer harmful side effects after taking their drugs, the Supreme Court has ruled in a 5-4 decision.

WASHINGTON — Generic drug makers cannot be held liable if patients suffer harmful side effects after taking their drugs, the Supreme Court has ruled in a 5-4 decision.

June 18, 2013

Half a loaf, the saying goes, is better than none. For the generic drug industry, that means that the Supreme Court handed it a partial victory Monday by ruling that “pay for delay” patent settlements between brand name and generic drug companies aren’t necessarily illegal and should be considered on a case-by-case, “rule of reason” approach by the Federal Trade Commission, which staunchly opposes the practice.

Half a loaf, the saying goes, is better than none. For the generic drug industry, that means that the Supreme Court handed it a partial victory Monday by ruling that “pay for delay” patent settlements between brand name and generic drug companies aren’t necessarily illegal and should be considered on a case-by-case, “rule of reason” approach by the Federal Trade Commission, which staunchly opposes the practice.

June 17, 2013

Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

NEW YORK — Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

May 13, 2013

The Food and Drug Administration's temporary stay pending its appeal of a district court decision ordering all levonorgestrel-based emergency contraceptives be available without a prescription and without any age restrictions was extended through May 28 by the U.S. Court of Appeals for the Second Circuit.

NEW YORK — The Food and Drug Administration's temporary stay pending its appeal of a district court decision ordering all levonorgestrel-based emergency contraceptives be available without a prescription and without any age restrictions was extended through May 28 by the U.S. Court of Appeals for the Second Circuit on Monday. 

The Second Circuit will entertain the appeal on that day. 

April 21, 2013

Last month, the Supreme Court heard Federal Trade Commission v. Actavis, which could impact the future of the generic drug industry at a time when 80% of all prescriptions dispensed in the United States are generic.

Last month, the Supreme Court heard Federal Trade Commission v. Actavis, which could impact the future of the generic drug industry at a time when 80% of all prescriptions dispensed in the United States are generic.

March 25, 2013

The Supreme Court heard arguments Monday in a case that could determine the future of generic drugs in America.

NEW YORK — The Supreme Court heard arguments Monday in a case that could determine the future of generic drugs in America.

The case, Federal Trade Commission v. Actavis, marks the latest attempt by federal authorities to put an end to what they say are deals between branded and generic drug companies that delay release of generic drugs to consumers.

March 5, 2013

The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

NEW YORK — The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

The case, FTC v. Actavis, will go before the high court on March 25 and may decide the future of patent settlements between branded and generic drug companies. The Generic Pharmaceutical Association filed an amicus brief with the court last week defending the settlements as beneficial to consumers.

February 11, 2013

A federal judge has ordered a California company and its owner to stop manufacturing and distributing drugs and dietary supplements in domestic commerce until their manufacturing operations comply with the Federal Food, Drug, and Cosmetic Act, the Food and Drug Administration reported.

SILVER SPRING, Md. — A federal judge has ordered a California company and its owner to stop manufacturing and distributing drugs and dietary supplements in domestic commerce until their manufacturing operations comply with the Federal Food, Drug, and Cosmetic Act, the Food and Drug Administration reported Friday. 

January 29, 2013

In an effort to quell the significant sway creditors wield in dictating terms with retail vendors, the National Community Pharmacists Association, the National Grocers Association and the National Association of Convenience Stores on Monday submitted a joint brief to the Supreme Court as amici curiae in the case of American Express vs. Italian Colors Restaurant.

ALEXANDRIA, Va. — In an effort to quell the significant sway creditors wield in dictating terms with retail vendors, the National Community Pharmacists Association, the National Grocers Association and the National Association of Convenience Stores on Monday submitted a joint brief to the Supreme Court as amici curiae, or "friends of the court," in the case of American Express vs. Italian Colors Restaurant. 

January 2, 2013

Consumers who purchased Chattem’s ACT Total Care Anticavity Fluoride Mouthwash between Jan. 1, 2009, and June 30, 2010, may be entitled to a cash refund from a class action settlement, according to a statement issued by the manufacturer.

SAN DIEGO — Consumers who purchased Chattem’s ACT Total Care Anticavity Fluoride Mouthwash between Jan. 1, 2009, and June 30, 2010, may be entitled to a cash refund from a class action settlement, according to a statement issued by the manufacturer.

December 21, 2012

A federal court decision means that a nontamper-resistant formulation of a painkiller made by Endo Health Solutions can enter the market early next month, the drug maker said.

CHADDS FORD, Pa. — A federal court decision means that a nontamper-resistant formulation of a painkiller made by Endo Health Solutions can enter the market early next month, the drug maker said.

The U.S. District Court for the District of Columbia dismissed a case filed by Endo subsidiary Endo Pharmaceuticals against the Food and Drug Administration, in which the company had argued that the FDA failed meet a legal obligation to determine whether the original formulation of Opana ER (oxymorphone) extended-release tablets was withdrawn from the market for safety reasons.

November 29, 2012

The Obama administration’s ambitious overhaul of the nation’s healthcare system weathered some significant challenges in 2012 and came through relatively unscathed.


The Obama administration’s ambitious overhaul of the nation’s healthcare system weathered some significant challenges in 2012 and came through relatively unscathed.


The first major test came in June, when the U.S. Supreme Court refused to overturn the Patient Protection and Affordable Care Act, while still ruling that the law’s provision requiring individuals to obtain health insurance was unconstitutional.


What saved the ACA was the court’s decision that the government’s mandate to purchase health insurance qualified as a tax. 


November 2, 2012

The National Retail Federation and more than a dozen retailers on Thusday asked a judge to reject a proposed class-action settlement of a federal antitrust lawsuit filed against Visa and MasterCard because of credit card swipe fees.

WASHINGTON — The National Retail Federation and more than a dozen retailers on Thusday asked a judge to reject a proposed class-action settlement of a federal antitrust lawsuit filed against Visa and MasterCard because of credit card swipe fees. The NRF suggested the settlement would not bring credit card swipe fees under control and does not give retailers who oppose it an adequate mechanism to opt out.

October 24, 2012

Mylan is challenging a federal court decision ordering the Food and Drug Administration to allow Watson Pharmaceuticals to launch a generic diabetes drug, Mylan said.

PITTSBURGH — Mylan is challenging a federal court decision ordering the Food and Drug Administration to allow Watson Pharmaceuticals to launch a generic diabetes drug, Mylan said.

The generic drug maker said it filed a motion in the U.S. District Court for the District of Columbia Tuesday to stay the court's order, which called on the FDA to let Watson launch a generic version of Takeda's Type 2 diabetes drug Actos (pioglitazone).

October 12, 2012

The Food and Drug Administration took the Family Smoking Prevention and Tobacco Control Act of 2009 one step closer to being considered by the Supreme Court earlier this week.

 SILVER SPRING, Md. — The Food and Drug Administration took the Family Smoking Prevention and Tobacco Control Act of 2009 one step closer to being considered by the Supreme Court earlier this week. The FDA recently petitioned the D.C. Circuit Court of Appeals to revisit the court's August decision that ruled in favor of the tobacco industry and precluded the FDA from mandating that graphic images depicting the consequences of smoking be placed on all cigarette packaging. 

October 11, 2012

A coalition — which includes the California Medical Association, the California Dental Association, California Pharmacists Association, National Association of Chain Drug Stores, California Association of Medical Product Suppliers, AIDS Healthcare Foundation and American Medical Response — continues to work to block the state of California from cutting Medi-Cal reimbursement rates by 10%.

SACRAMENTO, Calif. — A coalition — which includes the California Medical Association, the California Dental Association, California Pharmacists Association, National Association of Chain Drug Stores, California Association of Medical Product Suppliers, AIDS Healthcare Foundation and American Medical Response — continues to work to block the state of California from cutting Medi-Cal reimbursement rates by 10%.

September 11, 2012

The National Community Pharmacists Association and a number of independent pharmacy entities on Monday refiled its complaint against Express Scripts concerning its acquisition of Medco, demanding either Express Scripts be compelled to "unwind their merger" or alternatively be required to divest assets acquired from Medco.

 PITTSBURGH — The National Community Pharmacists Association and a number of independent pharmacy entities on Monday refiled its complaint against Express Scripts concerning its acquisition of Medco, demanding either Express Scripts be compelled to "unwind their merger" or alternatively be required to divest assets acquired from Medco. The independent pharmacy plaintiffs are also suing for the cost of the suit as well as "such other relief as the Court may deem just and proper."